| Aurora Optometric Group, P.c. | |
|
1 Liberty St, Arcade, NY 14009-1401 | |
| (585) 492-1958 | |
| (595) 496-5722 |
| Full Name | Aurora Optometric Group, P.c. |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 1 Liberty St, Arcade, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235330929 | NPI | - | NPPES |
| 00011387602 | Other | NY | UNIVERA GROUP # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 3521 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Aurora Optometric Group, P.c. 1 Liberty St, Arcade, NY 14009-1401 Ph: (585) 492-1958 | Aurora Optometric Group, P.c. 1 Liberty St, Arcade, NY 14009-1401 Ph: (585) 492-1958 |
News Archive
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
ProBioGen AG announced today that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.
A new study from the University of Ottawa Heart Institute, in collaboration with the Institute for Clinical Evaluative Sciences, has established that greater adoption of hospital-initiated tobacco cessation interventions improve patient outcomes and decrease further healthcare utilization.
The COVID-19 pandemic and resulting stay-at-home orders have taken a toll on many facets of physical and mental health in recent months. But according to new University of Colorado Boulder research, one silver lining may exist.
› Verified 4 days ago